Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedApr 13, 2026
DataAggregated Company Financials
Companies147
  • 7D2.3%
  • 3M-2.0%
  • 1Y6.8%
  • YTD-0.04%

Over the last 7 days, the Healthcare industry has risen 2.3%, driven by gains in Swedish Orphan Biovitrum and Camurus of 1.3% and 6.4%, respectively. During this same period, the OssDsign underperformed, falling 45%. In the last 12 months, the industry was up 9.4%. As for the next few years, earnings are expected to grow by 24% per annum.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 13 Apr 2026SEK 583.7bSEK 228.8b-SEK 2,930,915,803.9833.3x-199.1x2.6x
Wed, 11 Mar 2026SEK 563.5bSEK 228.5b-SEK 2,954,084,331.5729.5x-190.8x2.5x
Fri, 06 Feb 2026SEK 577.8bSEK 229.0b-SEK 1,987,563,633.8634.6x-290.7x2.5x
Sun, 04 Jan 2026SEK 580.0bSEK 230.4bSEK 3.7b41.3x157.8x2.5x
Tue, 02 Dec 2025SEK 601.0bSEK 230.8bSEK 3.6b42.8x167.5x2.6x
Thu, 30 Oct 2025SEK 612.4bSEK 228.1bSEK 3.5b46.8x177.3x2.7x
Sat, 27 Sep 2025SEK 593.6bSEK 227.1bSEK 6.6b43.5x89.8x2.6x
Mon, 25 Aug 2025SEK 631.7bSEK 227.2bSEK 6.3b49.1x100.4x2.8x
Wed, 23 Jul 2025SEK 624.8bSEK 227.5bSEK 6.7b45.4x93.7x2.7x
Fri, 20 Jun 2025SEK 593.9bSEK 226.7bSEK 5.9b45x101.4x2.6x
Sun, 18 May 2025SEK 610.2bSEK 224.9bSEK 5.6b36.5x108.9x2.7x
Tue, 15 Apr 2025SEK 540.7bSEK 221.8bSEK 5.3b33x102.8x2.4x
Thu, 13 Mar 2025SEK 538.6bSEK 206.1bSEK 4.7b35.4x114.9x2.6x
Sat, 08 Feb 2025SEK 600.9bSEK 220.4bSEK 2.5b42x237.5x2.7x
Mon, 06 Jan 2025SEK 588.1bSEK 202.6b-SEK 2,502,690,753.8640.4x-235x2.9x
Wed, 04 Dec 2024SEK 513.2bSEK 199.5b-SEK 2,880,920,309.9936.7x-178.1x2.6x
Fri, 01 Nov 2024SEK 535.3bSEK 199.9b-SEK 2,884,052,331.0636.6x-185.6x2.7x
Sun, 29 Sep 2024SEK 620.5bSEK 199.9b-SEK 2,815,696,552.4540.2x-220.4x3.1x
Tue, 27 Aug 2024SEK 605.0bSEK 200.0b-SEK 2,345,785,513.6837.5x-257.9x3x
Thu, 25 Jul 2024SEK 602.8bSEK 198.8b-SEK 2,866,260,337.4540.7x-210.3x3x
Sat, 22 Jun 2024SEK 557.3bSEK 195.4b-SEK 3,183,004,397.3135.3x-175.1x2.9x
Mon, 20 May 2024SEK 548.9bSEK 196.3b-SEK 2,920,494,830.6036.3x-188x2.8x
Wed, 17 Apr 2024SEK 520.9bSEK 193.0b-SEK 3,172,218,154.6944.3x-164.2x2.7x
Fri, 15 Mar 2024SEK 526.8bSEK 192.2b-SEK 3,668,152,341.1243.9x-143.6x2.7x
Sun, 11 Feb 2024SEK 509.6bSEK 191.4b-SEK 4,204,413,743.1548.9x-121.2x2.7x
Tue, 09 Jan 2024SEK 544.1bSEK 191.4b-SEK 965,813,732.0048.4x-563.4x2.8x
Thu, 07 Dec 2023SEK 510.8bSEK 190.4b-SEK 1,084,900,302.0050.3x-470.9x2.7x
Sat, 04 Nov 2023SEK 458.1bSEK 189.3b-SEK 1,100,030,806.0040.3x-416.4x2.4x
Mon, 02 Oct 2023SEK 450.7bSEK 185.0b-SEK 2,032,472,591.0035.4x-221.8x2.4x
Wed, 30 Aug 2023SEK 465.7bSEK 185.7b-SEK 1,768,733,347.0038.1x-263.3x2.5x
Fri, 28 Jul 2023SEK 477.8bSEK 183.4b-SEK 953,450,694.0040.9x-501.2x2.6x
Sun, 25 Jun 2023SEK 483.3bSEK 179.1b-SEK 798,027,738.0043.6x-605.6x2.7x
Tue, 23 May 2023SEK 523.4bSEK 177.4b-SEK 840,009,313.0043.4x-623.1x2.9x
Thu, 20 Apr 2023SEK 507.9bSEK 172.5b-SEK 1,420,459,366.0034.4x-357.5x2.9x
Price to Earnings Ratio

-357.5x


Total Market Cap: SEK 507.9bTotal Earnings: -SEK 1,420,459,366.00Total Revenue: SEK 172.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -162.3x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 2.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 9.9% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market4.42%
Healthcare2.34%
Life Sciences6.56%
Pharma4.81%
Healthcare Services3.22%
Medical Equipment2.20%
Biotech1.65%
Healthtech0.20%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 117x.
    • Analysts are expecting annual earnings growth of 20.2%, which is higher than its past year's earnings growth of 1.5% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 35% over the next 5 years.
  • This is better than its past earnings growth rate of 14% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 19% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SOBI Swedish Orphan BiovitrumSEK 406.201.3%
+SEK 1.9b		55.4%PE293.7x
CAMX CamurusSEK 514.506.4%
+SEK 1.8b		-8.5%PE41.8x
ALIF B AddLifeSEK 154.208.6%
+SEK 1.5b		3.7%PE33.6x
ASKER Asker Healthcare GroupSEK 71.905.3%
+SEK 1.4b		-6.6%PE59.7x
BONEX Bonesupport HoldingSEK 229.807.3%
+SEK 1.0b		-25.7%PE107.9x

Latest News

OSSD
SEK 3.50
OssDsign
7D
-44.6%
1Y
-74.6%
SOBI
SEK 406.20
Swedish Orphan Biovitrum
7D
1.3%
1Y
55.4%
ALIF B
SEK 154.20
AddLife
7D
8.6%
1Y
3.7%

ALIF B: Higher Margins And Dividend Outlook Will Support Future Upside

Analysts have maintained their SEK 187.50 price target on AddLife, with updated assumptions around discount rate, revenue growth, profit margin and future P/E that now reflect a slightly different balance of risk, earnings potential and valuation multiples. What's in the News AddLife AB (publ) announced an annual dividend of SEK 1.50 per share, with ex date on May 7, 2026, record date on May 8, 2026, and payment on May 13, 2026 (Key Developments).
BONEX
SEK 229.80
Bonesupport Holding
7D
7.3%
1Y
-25.7%
MCOV B
SEK 193.80
Medicover
7D
3.3%
1Y
-5.7%

MCOV B: Dividend Growth And 2028 Revenue Ambitions Will Support Upside

Analysts have nudged their Medicover price target higher to SEK227.29 from SEK225.05, citing updated assumptions that reflect a slightly higher discount rate, along with revised expectations for revenue growth, profit margins and future P/E. What's in the News The board proposes a dividend of €0.20 per share for the 2025 financial year, compared with €0.15 previously, subject to approval at the annual general meeting on 29 April 2026 (Key Developments).
HUM
SEK 47.35
Humana
7D
-2.6%
1Y
6.0%

Humana's (STO:HUM) Profits May Not Reveal Underlying Issues

Apr 06
Humana's (STO:HUM) Profits May Not Reveal Underlying Issues
SECT B
SEK 235.20
Sectra
7D
-0.2%
1Y
-7.7%

SECT B: Cloud Contracts And Rating Upgrades Will Shape Future Return Balance

Analysts have maintained the fair value estimate for Sectra at SEK 227.50. Recent upgrades and new price targets, which range from SEK 210 to SEK 250, support a slightly lower implied discount rate and marginally adjusted long-term growth and P/E assumptions.
VIMIAN
SEK 30.50
Vimian Group
7D
6.3%
1Y
-19.5%

VIMIAN: Margin Execution And New Bylaws Will Support Future Upside Potential

Analysts have reduced their price target for Vimian Group to SEK 25 from SEK 27, citing updated assumptions on margins and valuation multiples that result in a slightly adjusted fair value model. Analyst Commentary Recent research points to a more cautious stance on Vimian Group, with the updated SEK 25 price target reflecting revised assumptions on margins and valuation multiples rather than a shift in rating.
VICO
SEK 9.97
Vicore Pharma Holding
7D
-2.1%
1Y
53.4%
HNSA
SEK 30.72
Hansa Biopharma
7D
-6.0%
1Y
42.9%

HNSA: U.S. Kidney Transplant Approval Pathway Will Drive Potential Upside

Analysts have adjusted their price target on Hansa Biopharma by SEK 8, reflecting updated views on the risk profile and near term commercial opportunity for imlifidase, including its potential positioning in kidney transplantation and autoimmune indications. Analyst Commentary Recent research shows a mix of optimism and caution around Hansa Biopharma, with views shaped by the commercial outlook for imlifidase in kidney transplantation and autoimmune indications, as well as how quickly the company can execute on its plans.
CAMX
SEK 514.50
Camurus
7D
6.4%
1Y
-8.5%

CAMX: FDA Review Of Resubmitted NDA Will Drive Future Upside

Analysts have trimmed their 12 month price target for Camurus from SEK 660 to SEK 610, citing updated assumptions that include revised revenue growth, profit margin and future P/E expectations. What's in the News Camurus issued earnings guidance for 2026, with expected revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b, framed against internal 2025 expectations (Key Developments).
ASKER
SEK 71.90
Asker Healthcare Group
7D
5.3%
1Y
-6.6%
FLERIE
SEK 28.80
Flerie
7D
-3.0%
1Y
-30.5%
SANION
SEK 15.21
Saniona
7D
-7.0%
1Y
128.0%
IMP A SDB
SEK 49.30
Implantica
7D
7.3%
1Y
82.6%
DICOT
SEK 0.39
Dicot Pharma
7D
-6.9%
1Y
42.4%

Is Dicot Pharma (STO:DICOT) In A Good Position To Invest In Growth?

Feb 03
Is Dicot Pharma (STO:DICOT) In A Good Position To Invest In Growth?